Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel

Rhea-AI Summary

Akoya Biosciences (NASDAQ: AKYA) announces major innovations in spatial biology research at SITC 2024, introducing the PhenoCode Discovery IO60 panel and Mouse FFPE IO panel. The IO60 panel features 60 tumor and immunology markers, enabling comprehensive immune cell analysis with industry-leading throughput of over 16 samples per week. The Mouse FFPE IO panel includes 24 biomarkers for preclinical cancer research. Additionally, Akoya is expanding its PhenoCode catalog to support 100-biomarker experiments, making ultrahigh-plex spatial biology more accessible for laboratories.

Positive

• Launch of IO60 panel with 60 biomarkers enabling comprehensive immune cell analysis
• Industry-leading throughput capability of over 16 samples per week
• Introduction of 24-biomarker Mouse FFPE IO panel for preclinical research
• Expansion of PhenoCode catalog to support up to 100-biomarker experiments

Negative

• None.

Insights

Medical Research Analyst

The launch of PhenoCode Discovery IO60 and Mouse FFPE IO panels represents a significant advancement in spatial biology research capabilities. The 60-biomarker IO60 Panel offers unprecedented throughput with 16+ samples per week, making it the fastest ultrahigh-plex system available. This technology enables deeper analysis of the tumor microenvironment and immune responses in a single workflow.

The mouse FFPE IO panel with 24 biomarkers fills a important gap in preclinical research, facilitating better translation between animal models and human studies. The expansion to support 100-biomarker experiments through the PhenoCode catalog demonstrates scalability and accessibility for broader research applications.

While these innovations show technical promise, market adoption and revenue impact will depend on research budget allocations and competition in the spatial biology space. The focus on streamlined workflows and increased throughput could drive operational efficiencies for research institutions.

Market Research Analyst

The timing of this product launch aligns with growing demand in the immuno-oncology research market. The technology addresses key bottlenecks in spatial biology research, particularly speed and scalability. Market differentiation through industry-leading throughput and comprehensive marker panels positions Akoya competitively in the research tools sector.

The expansion into preclinical research tools with the mouse FFPE panel opens additional revenue streams in the pharmaceutical R&D segment. The strategy to make ultrahigh-plex spatial biology accessible to all laboratories could expand the total addressable market. However, success will depend on pricing strategy and adoption rates among academic and pharmaceutical research centers.

Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research

Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research insights

Expands the PhenoCode catalog with barcodes that enable ultrahigh-plex, 100-biomarker experiments, making scalable spatial biology research accessible for every lab

MARLBOROUGH, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ^®, will unveil innovations designed to accelerate insights in immuno-oncology (IO) and advance preclinical research at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The company will present its latest offerings, including the groundbreaking ultrahigh-plex PhenoCode Discovery IO60 panel encompassing 60 tumor and immunology markers and a panel for spatial phenotyping of murine cancer models in preclinical studies at SITC booth #833.

PhenoCode Discovery IO60 Panel: Setting A New Standard for IO Research

The new 60-biomarker IO60 Panel addresses the growing need for a comprehensive IO panel that includes an extensive set of fully validated markers. This ready-to-use solution offers researchers the ability to interrogate a wide array of immune cell types, along with key checkpoint inhibitors, components of the tumor microenvironment, and known immunotherapy targets in a single, streamlined workflow.

Akoya’s PhenoCycler-Fusion 2.0 platform enhances the panel’s capabilities, delivering unmatched speed and scale, allowing over 16 samples to be processed per week, the industry’s fastest ultrahigh-plex throughput.

"The IO60 Panel sets a new standard for IO research, providing scientists with the robust marker depth needed to more efficiently address complex research questions," said Brian McKelligon, CEO of Akoya Biosciences. "By offering a fully optimized solution, we are enabling researchers to ask critical questions around immune response, immune evasion, and the tumor microenvironment with unparalleled speed, resolution, and throughput."

Mouse FFPE Panel: Enhance Translational Insights in Preclinical Cancer Research

Akoya is also introducing a 24-biomarker mouse formalin-fixed paraffin-embedded (FFPE) IO antibody panel for single-cell spatial phenotyping of key immune cell types in the tumor microenvironment. This panel covers essential immune cell lineage and structural markers, enabling advanced research and comparative studies between mouse and human models to deepen the understanding of cancer biology. The panel is designed to support preclinical research using FFPE samples.

"Our new mouse FFPE IO panel empowers biopharma researchers with a tool that can enhance the translational potential of their preclinical studies," said Peter Miller, Vice President of R&D, Akoya Biosciences. "With this new offering, we’re extending the impact of spatial biology in critical stages of drug development, providing the tools to explore key biological insights early in the therapeutic pipeline."

Making 100-Biomarker Experiments Accessible for Every Lab

Driven by a transformative vision to make ultrahigh-plex spatial biology accessible to all, Akoya is expanding its PhenoCode catalog of molecular barcodes. These additions empower researchers to scale their experiments seamlessly from 10 to 100s of biomarkers, using the same chemistry. With all barcoded antibodies added simultaneously, assay development becomes straightforward. Moreover, gentle isothermal elution of molecular barcodes allows unlimited cycling without compromising tissue integrity, easily supporting ultrahigh-plex spatial phenotyping.

“Designed from insights gathered across 1,500+ publications, our new panels and molecular barcodes embody Akoya’s commitment to accessible spatial biology,” said Niro Ramachandran, Chief Business Officer of Akoya Biosciences. “Built on the foundation of our molecular barcoding chemistry – a scalable, gentle yet straightforward approach, and manufactured at our Center of Excellence, these content innovations provide researchers with true comprehensive spatial analysis—breaking traditional barriers in speed, throughput, and resolution to make ultrahigh-plex spatial biology impactful and accessible for every lab."

Akoya Biosciences at SITC 2024

Akoya will be showcasing these new products for both the research and clinical settings at Booth #833 at SITC 2024. The company will also feature presentations on the IO60 and mouse IO panels and showcase the capabilities of the PhenoCycler^®-Fusion 2.0 and PhenoImager^® HT 2.0 systems.

Topic: Catalyzing the Next Wave in Spatial Discoveries and Patient Care
Date: Friday, November 8th
Time: 5:30 PM - 6:00 PM
Location: Akoya Biosciences Booth #833

Topic: How Spatial Biology is Shaping Next-Generation Cancer Treatment
Date: Saturday, November 9^th
Time: 1:00 PM - 1:30 PM
Location: Akoya Biosciences Booth #833

For more information about Akoya’s presence at SITC 2024, the newly unveiled PhenoCode Discovery IO60, mouse FFPE IO panel, and the roadmap to 100-Plex capability, please visit https://sb.akoyabio.com/SITC2024

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding the capabilities, impact, potential and utility of our products and services and other statements regarding our business strategies, performance and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Akoya Biosciences

As The Spatial Biology Company^®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler^®, PhenoImager^® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
investors@akoyabio.com

Media Contact:
Christine Quern
617-650-8497
media@akoyabio.com

FAQ

What is the new PhenoCode Discovery IO60 panel announced by Akoya Biosciences (AKYA)?

The PhenoCode Discovery IO60 is a 60-biomarker panel for immuno-oncology research that enables comprehensive analysis of immune cell types, checkpoint inhibitors, and tumor microenvironment components in a single workflow.

What is the sample processing capacity of Akoya's (AKYA) new IO60 panel?

Using the PhenoCycler-Fusion 2.0 platform, the IO60 panel can process over 16 samples per week, which Akoya claims is the industry's fastest ultrahigh-plex throughput.

What is the Mouse FFPE IO panel launched by Akoya Biosciences (AKYA)?

The Mouse FFPE IO panel is a 24-biomarker antibody panel designed for single-cell spatial phenotyping of immune cell types in the tumor microenvironment, specifically for preclinical cancer research using FFPE samples.